Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive single-molecule digital immunoassay services for quantifying low-abundance Type 2 and allergic inflammatory cytokines—including Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-13 (IL-13), Interleukin-33 (IL-33), and Thymic Stromal Lymphopoietin (TSLP)—in plasma, serum, BALF, mucosal secretions, and cell supernatants down to sub-picogram per milliliter limits.
By overcoming the detection barriers that leave basal Th2 mediators unquantified on conventional ELISA or standard multiplex arrays, our Simoa facility enables baseline stratification and longitudinal pharmacodynamic monitoring across preclinical allergic, atopic, and tissue-remodeling pipelines.
Establishing standardized bioanalytical parameters to ensure high data integrity across dynamic allergic cascades.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Challenge & Kinetic Timing | Acute allergen challenge (2–6h: TSLP/IL-33) vs. late-phase peak (24–72h: IL-4/IL-5/IL-13) | Aligns biofluid draws with physiological release waves rather than arbitrary calendar schedules. |
| Baseline & Vehicle Controls | Pre-sensitization intra-individual baselines vs. non-challenged naive control cohorts | Separates true drug-mediated Th2 suppression from spontaneous post-challenge resolution. |
| Effector vs. Alarmin Staging | Pairing upstream alarmins (TSLP, IL-33) with downstream effectors (IL-5, IL-13, total IgE) | Establishes the exact point of pathway interruption for novel targeted therapeutics. |
| Micro-Volume Allocation | 15 μL net volume per well, duplicate verification reserve, and orthogonal follow-up | Conserves longitudinal small-animal biofluids across multi-week chronic challenge models. |
| Plate Layout & Balancing | Randomizing challenge arms, dose escalation groups, and serial timepoints across runs | Eliminates confounding between true experimental treatment effects and run-to-run bioanalytical variance. |
Validated single-analyte and multiplex digital immunoassay configurations for ultra-sensitive Th2 bioanalysis.
| Target Analyte | Biomarker Role & Pathway Specificity | Functional LLOQ (pg/mL) | Dynamic Range (pg/mL) | Primary Research Focus |
|---|---|---|---|---|
| IL-4 | Th2 Differentiation & IgE Isotype Switching | 0.020 | 0.020 – 500 | Atopic dermatitis, allergic asthma, B-cell humoral responses, Th2 skewing models |
| IL-5 | Eosinophil Maturation, Activation & Survival | 0.030 | 0.030 – 500 | Eosinophilic asthma, hypereosinophilic syndromes, anti-IL-5 therapeutic PD monitoring |
| IL-13 | Mucus Hypersecretion & Tissue Fibrosis | 0.030 | 0.030 – 600 | Airway remodeling, pulmonary fibrosis, atopic eczema, goblet cell hyperplasia |
| IL-33 | Epithelial Alarmin / ST2 Receptor Ligand | 0.050 | 0.050 – 800 | Epithelial barrier disruption, innate ILC2 activation, acute mucosal inflammation |
| TSLP | Epithelial Alarmin / Dendritic Cell Priming | 0.040 | 0.040 – 800 | Upstream allergic priming, atopic march models, anti-TSLP biologic evaluation |
| IL-17A | Th17 / Mixed Granulocytic Airway Inflammation | 0.050 | 0.050 – 1,000 | Severe steroid-resistant asthma, neutrophilic airway inflammation, psoriasis models |
| Multi-Plex Th2 Core | Combined IL-4, IL-5, IL-13, and IL-6 | 0.010 – 0.030 | 0.010 – 1,000 | Comprehensive Type 2 effector profiling from a single 15 μL biofluid sample aliquot |
Evaluating analytical performance, multiplex capacity, sample volume consumption, and detection boundaries across bioanalytical platforms.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | 10.0 – 50.0 pg/mL | 1.0 – 10.0 pg/mL | 0.5 – 5.0 pg/mL | 0.010 – 0.050 pg/mL (Sub-pg/mL) |
| Basal Blood Detectability | <15% (Severe dropout in blood) | 40% – 60% | 60% – 80% (Stimulated models) | 100% Quantifiable across healthy cohorts |
| Sample Consumption per Test | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Mucosal & BALF Micro-Fluids | Challenging (Requires pooling) | Moderate | Moderate | Excellent (High recovery in micro-fluids) |
| Linear Dynamic Range | 2.0 logs | 3.0 – 3.5 logs | 4.0 – 5.0 logs | >4.5 logs (Poisson digital + Analog) |
| Serial Rodent Survival Bleeds | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial tail-vein / submandibular) |
| Primary Matrix Fit | High-titer in vitro supernatants | Broad discovery screening | Lysates, stimulated biofluids | Plasma, serum, BALF, mucosal washes |
Cross-platform transitions from legacy plate ELISA, Luminex, or MSD systems to digital Simoa require structured bioanalytical method bridging. Differences in antibody clone affinities, synthetic calibrator constructs, incubation kinetics, and matrix dilution factors commonly generate numerical shifts in absolute values, even when inter-platform rank correlations exceed r = 0.95.
Our Bridging Protocol: We test a representative pilot subset (15–20 paired baseline and elevated research specimens) in parallel across both platforms to establish a validated mathematical conversion equation, ensuring longitudinal dataset continuity across multi-year drug discovery campaigns.
Bioanalytical parameters established according to rigorous fit-for-purpose biomarker validation guidelines.
Specialized pre-analytical diluents overcoming surfactant and mucin protein interference to achieve 80–120% spike recovery in lavage fluids.
Validated parallelism across upstream epithelial alarmins (TSLP, IL-33) and effector interleukins (IL-4, IL-5, IL-13) in complex biofluids.
Functional LLOQs (0.020–0.030 pg/mL) enabling quantification of deep target suppression following low-dose therapeutic candidate administration.
Barcode verification on dry ice, assessment of mucosal viscosity/lipemia, cataloged into monitored -80°C biobanking.
Automated liquid handling performs 1:4 dilution in matrix-matched diluent supplemented with heterophilic blocking agents.
Capture antibodies covalently coated on paramagnetic beads bind target Th2 cytokines, followed by biotinylated detector binding and SBG labeling.
Bead-enzyme complexes are loaded into 216,000 microwells on Simoa discs, oil-sealed, and imaged for digital Poisson counting (AEB).
Software algorithms interpolate AEB values against calibration curves to output absolute pg/mL concentrations, replicate CVs, and QC metrics.
Standardized pre-analytical protocols ensuring Th2 cytokine stability and eliminating matrix-induced suppression.
| Pre-Analytical Parameter | Why It Matters for Type 2 Cytokines | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Heparin can cause charge-based aggregation of basic cytokines; K2-EDTA preserves antigen stability. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted for 30–60 min at RT and promptly centrifuged. |
| Centrifugation Protocol | Platelet degranulation and leukocyte lysis release intracellular cytokines, falsely elevating baselines. | Centrifuge at 2,000 × g for 15 min at 4°C within 60 minutes of collection; harvest cell-free supernatant. |
| BALF & Mucosal Fluid Handling | Mucus viscosity and cellular debris cause non-specific bead clumping and variable recovery. | Centrifuge BALF (400 × g for 10 min at 4°C) to remove cells; harvest supernatant; avoid excessive vortexing. |
| Freeze-Thaw Management | Th2 cytokines undergo conformational degradation upon repeated freeze-thaw cycles. | Aliquot immediately into polypropylene cryovials; store at -80°C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Single-molecule digital counting requires minimal specimen input, conserving small-animal biofluids. | 15 μL net volume per well (30–50 μL recommended for duplicate verification and reserve). |
Applying ultra-sensitive single-molecule Th2 cytokine measurements across allergy modeling and therapeutics evaluation.
Track basal and allergen-provoked IL-4, IL-5, and IL-13 in mouse ovalbumin (OVA) and house dust mite (HDM) challenge models.
Quantify dermal and systemic Th2 cytokines alongside epithelial TSLP release in murine atopic dermatitis models.
Assess target engagement and pharmacodynamic suppression for Dupilumab and Mepolizumab biosimilars.
Measure hyper-acute release of IL-33 and TSLP (0–6h) following environmental allergen, protease, or detergent insult.
Correlate circulating IL-5 and IL-13 concentrations with tissue eosinophil infiltration and subepithelial collagen deposition.
Measure complete Type 2 cytokine signatures from micro-volume lavage fluids, nasal secretions, and ocular washes.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Key peer-reviewed studies establishing single-molecule Th2 cytokine sensitivity and translational allergy study designs.
Study Design Takeaway: Establishes the foundational physics of digital Poisson single-molecule enzyme counting in femtoliter microwells, demonstrating up to 1000-fold sensitivity gains over conventional ELISA.
Study Design Takeaway: Demonstrates robust single-molecule quantification of basal cytokines in human plasma and establishes practical method-bridging parameters against legacy multiplex systems.
Study Design Takeaway: Outlines the sequential role of epithelial alarmins (TSLP, IL-33) and effector Th2 cytokines (IL-4, IL-5, IL-13) in driving allergic pathology, validating multi-marker profiling.
Study Design Takeaway: Validates the automated engineering and single-molecule accuracy of dye-encoded magnetic beads in digital immunoassay bioanalysis.
Addressing common bioanalytical and project planning inquiries.
In healthy individuals and unprovoked animal models, circulating concentrations of IL-4, IL-5, and IL-13 are extremely low (typically 0.02–0.50 pg/mL). Conventional plate ELISA and standard multiplex assays have LLOQs around 10–50 pg/mL, resulting in high rates of non-detectable values. Simoa provides functional LLOQs down to 0.02 pg/mL, delivering 100% quantifiable baseline data.
Yes. Our bioanalytical protocols are validated for bronchoalveolar lavage fluid (BALF), nasal washes, tear fluid, sputum supernatants, and dermal interstitial fluid. We assess minimum required dilution (MRD) to eliminate matrix-specific viscosity or non-specific binding.
By accurately measuring sub-picogram baseline levels, Simoa enables researchers to quantify dose-dependent target suppression following drug administration. In contrast, standard assays cannot measure decreases below 10 pg/mL, making efficacy tracking impossible in low-titer cohorts.
The standard protocol requires only 15 μL of neat sample volume per well (which is diluted 1:4 on-board to a 60 μL working volume). We recommend providing 30–50 μL total volume to support dead volume and duplicate verification.
Cross-platform comparisons should be treated as a formal method bridging exercise. While relative group rankings and fold-changes correlate strongly (r > 0.95), variations in calibrator constructs, antibody affinities, and dilution factors introduce minor numerical offsets. We provide paired bridging studies to establish mathematical conversion algorithms for long-term programs.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×